PRKCD

Across TCGA pan-cancer cohorts, PRKCD mass-spec protein differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of PRKCD’s most consistent transcriptional readouts.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where PRKCD mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types PRKCD is over-expressed in tumor, although a few such as CCRCC and LSCC show the opposite, repressed pattern.

PDAC, CCRCC, and LSCC are the cancer types where PRKCD tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in PRKCD mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
PDAC	Female	II,III,IV	+0.401	<.001	7	view →
CCRCC	Male	All	−0.242	<.001	7	view →
LSCC	Male	II,III,IV	−0.209	<.001	4	view →
HNSC	All	All	+0.109	.008	4	view →
OV	All	All	+0.429	.003	2	view →
LUAD	All	All	+0.086	.009	2	view →
COAD	All	II,III,IV	+0.072	.042	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

PRKCD–PDAC

Open the PDAC breakdown →